117: Sustainability data strategy for Pfizer small molecule portfolio

Abstract: Earlier in the 2020s, Pfizer announced the ambitious goal of becoming net zero by 2040. As pharmaceutical companies face climate change operationally and strategically, different approaches will be required for the swath of work undertaken. This poster will dive into how Pfizer’s small molecule API is being tackled and how we are positioning ourselves for continued success. We will discuss how API life-cycle analyses are produced, communicated, and worked upon within our workflows along with the integration of drug product workflows. Within Pfizer’s Chemical Research & Development (CRD), our 2030 vision has brought forth sustainability as one of the pillars alongside speed, cost, and efficiency, making it imperative to process development. This integration of a key factor has led to mass accumulation of data, which is yielding insights into new areas. As continued development occurs in this space, it is crucial that data quality is consistent and maintained. We will discuss further efforts for digitization, automation, and increased breadth and depth of data collection.